This report examines how new technologies can emerge in the face of economic pressures that may affect the demand for nuclear imaging, and how healthcare reforms are impacting nuclear medicine. The advent of hybrid imaging has enabled PET/CT imaging to undergo explosive growth. However, this has been at the cost of an increased demand on struggling healthcare budgets. PET and SPECT imaging are well established techniques within nuclear imaging, and are the main focus of this report PET imaging uses Positron Emitting radioactive tracers with a short half life, to image metabolically active organs PET combined with CT allows precise anatomical imaging of the body, identifying diseased areas depending upon the tracer used PET/CT is most often used for cancer diagnosis PET/MRI is a new technique that was introduced to reduce patient exposure to radiation PET only systems are now generally considered obsolete, due to the superior imaging quality of PET/CT

An early diagnosis of disease is the foundation of increasing survival rates. Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging are diagnostic imaging techniques that are widely used in a variety of disease areas including oncology, cardiovascular disease, bone disease, and infectious disease. This report provides an analysis of the nuclear imaging market, with a particular focus on SPECT and PET imaging and hybrid modalities within the 5EU (France, Germany, Italy, Spain, and UK).

Scope

• An overview of Nuclear Imaging, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized EU Nuclear Imaging market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
• Investigation of current and future market competition for Nuclear Imaging.
• Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
• Competitor assessment including device approval analysis and device sales forecasts.
• Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
• Analysis of unmet needs within the market and opportunities for future players.
• Technology trends evaluation to assess strength of pipeline.
• An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
• Company profiles including business description, financial overview and SWOT analysis.
• Coverage of key market players.
• Strategic assessment of the Nuclear Imaging sector through market impact analysis, future market scenario and company analysis.
• Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

• Understand the trends shaping and driving EU Nuclear Imaging market.
• Realize device preferences of physicians who have performed the tests already.
• Access market sizing, forecasts and quantified growth opportunities in EU Nuclear Imaging market through 2018.
• Quantify candidate patient populations to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
• Perform benchmarking analysis of growth opportunities against currently marketed products.
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
• What’s the next big thing in EU Nuclear Imaging market landscape? Identify, understand and capitalize.

Table of Contents

1 Table of Contents 6
1.1 List of Tables 13
1.2 List of Figures 16

2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 18

3 Industry Overview 19
3.1 Nuclear Imaging Techniques 19
3.1.1 Positron Emission Tomography 19
3.1.2 Single-Photon Emission Computed Tomography 21
3.1.3 Planar Scintigraphy 21
3.1.4 Hybrid Imaging 22
3.2 Clinical Applications of Nuclear Imaging Technology 27
3.2.1 Cancer 27
3.2.2 Cardiology 29
3.2.3 Neurology 31
3.2.4 Infection and Inflammation 33
3.3 Advantages and Disadvantages of Nuclear Imaging Technologies 36
3.4 Market Access 37
3.4.1 Product Life Cycle 37
3.4.2 Purchasing Decisions 39
3.4.3 Equipment Leasing 45
3.4.4 Replacement of PET/CT by PET/MRI 45
3.5 Reimbursement 50
3.5.1 Overview 50
3.5.2 France 51
3.5.3 Germany 52
3.5.4 Italy 54
3.5.5 Spain 54
3.5.6 UK 55
3.6 Procedure Trends 56
3.6.1 France 56
3.6.2 Germany 59
3.6.3 Italy 62
3.6.4 Spain 64
3.6.5 UK 66
3.7 Regulatory Issues/Recalls 69
3.8 M&As and Key Partnerships 69
3.9 Economic Impact 72

4 Unmet Needs 73
4.1 Overview 73
4.2 Improved Reimbursement for New Techniques 73
4.3 Lack of Binding Clinical Guidelines 77
4.4 Patient Comfort and Convenience 77
4.5 Reducing Radiation Exposure 78
4.6 Improved Scanner Performance 80
4.7 Image Processing Software Improvements 81
4.8 Increased Risk of Artifacts in Hybrid Images 83
4.9 Demand for New Radiotracers 84
4.10 Improved Clinical Input into the Design Process 86

5 Market Opportunity Analysis 87
5.1 Cheaper, Simpler Nuclear Imaging Devices 87
5.2 SPECT/CT in Developing Countries 87
5.3 Increased Demand for Teleradiology Services 89

6 Market Drivers and Barriers 91
6.1 Driver: Aging Population and Increasing Disease Prevalence 91
6.2 Driver: Referring Physician Awareness 92
6.3 Driver: Defensive medicine 93
6.4 Driver: Patient Awareness 95
6.5 Driver: Self-Referral 95
6.6 Driver: New Imaging Agents 96
6.7 Driver: Increasing Demand for Cancer Diagnostic Tests 96
6.8 Driver: Companion Diagnostic Testing 97
6.9 Barrier: Comparative Effectiveness Research 98
6.10 Barrier: Reimbursement Legislation 100
6.11 Barrier: Increasing Demand for Nuclear Imaging in Developing Markets 100
6.12 Barrier: Insurance Company Lobbying to Reduce Unnecessary Imaging 102
6.13 Barrier: Greater Payer Scrutiny of EMRs 102
6.14 Barrier: Increased Use of Appropriateness Criteria 103
6.15 Barrier: Practice Guidelines to Reduce Unnecessary Procedures 105
6.16 Barrier: Imaging Facility Accreditation 105
6.17 Barrier: Loss of Nuclear Medicine Skills 106
6.18 Barrier: High Cost of Instruments and Reagents 107
6.19 Barrier: Radiopharmaceutical Cost and Supply Difficulties 108
6.20 Barrier: Hospital Consolidation 111

7 Competitive Assessment 112
7.1 Overview 112
7.2 Dedicated PET Systems 112
7.2.1 Overview 112
7.2.2 Product Profile 113
7.2.3 SWOT Analysis 114
7.3 PET/CT Systems 114
7.3.1 Overview 114
7.3.2 Product Profiles 115
7.3.3 SWOT Analysis 117
7.4 PET/MRI Systems 117
7.4.1 Overview 117
7.4.2 Product Profile 119
7.4.3 SWOT Analysis 120
7.5 Dedicated SPECT Systems 120
7.5.1 Overview 120
7.5.2 Product Profile 122
7.5.3 SWOT Analysis 123
7.6 SPECT/CT Systems 124
7.6.1 Overview 124
7.6.2 Product Profile 126
7.6.3 SWOT Analysis 127
7.7 PET/Ultrasound and SPECT/Ultrasound Systems 128
7.7.1 Overview 128
7.7.2 Product Profile 128
7.7.3 SWOT Analysis 129

8 Pipeline Assessment 130
8.1 Overview 130
8.2 Pipeline by Phases in Development 130
8.3 Product Profiles 131
8.3.1 Brain Biosciences CerePET 131
8.3.2 ECORAD Dual Modality Imager 132
8.3.3 FMI Technologies ScintiStar PET/CT 133
8.3.4 IntraMedical Imaging Marginator Beta Camera 135
8.3.5 INSERT SPECT/MRI 136
8.3.6 Nucare/Zecotek Photonics New Generation PET Scanning Device 139
8.3.7 Philips Healthcare PET Alpha Ring Detector 140
8.3.8 Photo Diagnostic Systems NeuroPET/CT 141
8.3.9 SynchroPET Breast PET/MRI 142
8.3.10 SynchroPET Wrist Scanner 143
8.3.11 SurgicEye SPECT Hybrid 144

9 Clinical Trials to Watch 146
9.1 Overview 146
9.2 Clinical Trial Profiles 146

10 Current and Future Players 149
10.1 Overview 149
10.2 Trends in Corporate Strategy 149
10.3 Company Profiles 150
10.3.1 DDD-Diagnostic 150
10.3.2 Digirad 152
10.3.3 GE Healthcare 156
10.3.4 GVI Medical Devices 161
10.3.5 Mediso Medical Imaging Systems 164
10.3.6 NeuroLogica 166
10.3.7 Neusoft Medical Systems 168
10.3.8 NuCare Medical Systems 171
10.3.9 Oncovision 173
10.3.10 Philips Healthcare 175
10.3.11 Shimadzu 182
10.3.12 Siemens Healthcare 187
10.3.13 SurgicEye 192
10.3.14 Toshiba Medical 195
10.3.15 Other Companies 200

11 Market Outlooks 202
11.1 Company Market Share Analysis 202
11.1.1 Overview 202
11.1.2 France 203
11.1.3 Germany 203
11.1.4 Italy 204
11.1.5 Spain 205
11.1.6 UK 206
11.2 Market Segment Share 206
11.2.1 SPECT & SPECT/CT 206
11.2.2 PET, PET/CT & PET/MRI 208
11.3 By Geography 210
11.3.1 Overview 210
11.3.2 France 211
11.3.3 Germany 213
11.3.4 Italy 216
11.3.5 Spain 218
11.3.6 UK 221

12 Appendix 225
12.1 Abbreviations 225
12.2 Bibliography 230
12.3 Methodology 259
12.3.1 Overview 259
12.3.2 Coverage 259
12.3.3 Secondary Research 259
12.4 Physicians and Specialists Included in This Study 261
12.5 Primary Research 263
12.5.1 Primary Research - Key Opinion Leader Interviews 263
12.5.2 Expert Panel Validation 263
12.5.3 Stakeholder Survey 264
12.6 Forecasting Methodology 266
12.7 About the Authors 267
12.7.1 Andrew Thompson, PhD, Senior Analyst 267
12.7.2 Priya Radhakrishnan, MBA, Director, Medical Devices 267
12.7.3 Bonnie Bain, PhD, Global Head of Healthcare 268
12.8 About GlobalData 269
12.9 Disclaimer 269

List of Tables

Table 1: Applications of Nuclear Imaging 27
Table 2: FDG-PET Diagnostic Accuracy for Specific Cancers 28
Table 3: Potential Clinical Benefits of Hybrid Nuclear Imaging in Cardiology 31
Table 4: Applications of PET Imaging in Non-Cancer Neurology 32
Table 5: Applications of SPECT Imaging in Non-Cancer Neurology 32
Table 6: Characteristics of SPECT, PET, Ultrasound, CT, and MRI 37
Table 7: The Age of Canada's Hospital-Based Medical Technology Inventories, Relative to ECCREI Rules, 2009 38
Table 8: Nuclear Imaging Trends in France, 2012-2020 58
Table 9: Nuclear Imaging Trends in Germany, 2012-2020 61
Table 10: Nuclear Imaging Trends in Italy, 2012-2020 63
Table 11: Nuclear Imaging Trends in Spain, 2012-2020 65
Table 12: Nuclear Imaging Trends in UK, 2012-2020 68
Table 13: Recent Device Recalls in the Nuclear Imaging Market 69
Table 14: Recent Key Events in the Nuclear Imaging Market 71
Table 15: Nuclear Imaging Market Drivers and Barriers 91
Table 16: Duplicate Diagnostic Test Incidence in France, Germany, UK, and US 103
Table 17: Dedicated PET Scanners 113
Table 18: Dedicated PET SWOT Analysis 114
Table 19: PET/CT Scanners 115
Table 20: PET/CT SWOT Analysis 117
Table 21: PET/MRI Systems 119
Table 22: PET/MRI SWOT Analysis 120
Table 23: Dedicated SPECT Systems 122
Table 24: Dedicated SPECT SWOT Analysis 123
Table 25: SPECT/CT Systems 126
Table 26: SPECT/CT SWOT Analysis 127
Table 27: SPECT-Ultrasound Systems 128
Table 28: SPECT/Ultrasound SWOT Analysis 129
Table 29: Nuclear Imaging Pipeline, 2014 130
Table 30: CerePET SWOT Analysis 132
Table 31: ECORAD Dual Modality Imager SWOT Analysis 133
Table 32: ScintiStar PET/CT SWOT Analysis 135
Table 33: Marginator SWOT Analysis 136
Table 34: INSERT SPECT-MRI SWOT Analysis 139
Table 35: Nucare/Zecotek Photonics New Generation PET Scanning Device SWOT Analysis 140
Table 36: PET Alpha Ring Detector 141
Table 37: NeuroPET/CT Scanner SWOT Analysis 142
Table 38: SynchroPET Breast PET/MRI SWOT Analysis 143
Table 39: SynchroPET Wrist Scanner 144
Table 40: SurgicEye SPECT/Ultrasound device SWOT Analysis 145
Table 41: Key Clinical Trials 147
Table 42: Company Profile - DDD-Diagnostic 150
Table 43: DDD-Diagnostic SWOT Analysis 152
Table 44: Company Profile - Digirad 153
Table 45: Digirad SWOT Analysis 156
Table 46: Company Profile - GE Healthcare 157
Table 47: GE Healthcare Product Portfolio 158
Table 48: GE Healthcare SWOT Analysis 161
Table 49: Company Profile - GVI Medical Devices 162
Table 50: GVI Medical Devices SWOT Analysis 163
Table 51: Company Profile - Mediso Medical Imaging Systems 164
Table 52: Mediso Medical Imaging Systems SWOT Analysis 165
Table 53: Company Profile - Neurologica 166
Table 54: Neurologica SWOT Analysis 168
Table 55: Company Profile - Neusoft Medical Systems 169
Table 56: Neusoft Medical Systems SWOT Analysis 171
Table 57: Company Profile - NuCare Medical Systems 172
Table 58: Nucare Medical Systems SWOT Analysis 173
Table 59: Company Profile - Oncovision 174
Table 60: Oncovision SWOT Analysis 175
Table 61: Company Profile - Philips Healthcare 176
Table 62: Philips Healthcare SWOT Analysis 182
Table 63: Company Profile - Shimadzu 183
Table 64: Shimadzu SWOT Analysis 186
Table 65: Company Profile - Siemens Healthcare 187
Table 66: Siemens Healthcare SWOT Analysis 192
Table 67: Company Profile - SurgicEye 193
Table 68: SurgicEye SWOT Analysis 195
Table 69: Company Profile - Toshiba Medical 196
Table 70: Toshiba Medical SWOT Analysis 199
Table 71: Other Companies in the Nuclear Imaging Market, 2014 200
Table 72: EU5 Market Value Forecast by Market Segment for SPECT & SPECT/CT (2012-2020) 207
Table 73: EU5 Market Value Forecast by Market Segment for PET, PET/CT & PET/MRI (2012-2020) 209
Table 74: EU5 Sales of PET and SPECT Imaging Systems, 2012-2020 211
Table 75: France Market Value Forecast by Market Sub segment (2012-2020) 212
Table 76: Germany Market Value Forecast by Market Sub segment (2012-2020) 214
Table 77: Italy Market Value Forecast by Market Sub-segment (2012-2020) 216
Table 78: Spain Market Value Forecast by Market Sub-segment (2012-2020) 219
Table 79: UK Market Value Forecast by Market Sub-segment (2012-2020) 222
Table 80: Primary Research Summary 264
Table 81: Primary Research Participants Affiliation 265

List of Figures

Figure 1: Cyclotron Distribution in 10 Countries 20
Figure 2: Localization of Tumor in Chest Cavity by PET, CT, and PET/CT 24
Figure 3: Mutually Beneficial Effects of PET/MRI Imaging 26
Figure 4: Nuclear Imaging Trends in France, 2012-2020 58
Figure 5: Nuclear Imaging Trends in Germany, 2012-2020 61
Figure 6: Nuclear Imaging Trends in Italy, 2012-2020 63
Figure 7: Nuclear Imaging Trends in Spain, 2012-2020 65
Figure 8: Nuclear Imaging Trends in UK, 2012-2020 68
Figure 9: Imaging Utilization Rates (Number of Outpatient Visits with MRI/CT per 1,000 Persons), by Year in the US 92
Figure 10: EU5 Company Market Shares for Nuclear Imaging Equipment (2012) 202
Figure 11: France Company Market Shares for Nuclear Imaging Equipment (2012) 203
Figure 12: Germany Company Market Shares for Nuclear Imaging Equipment (2012) 204
Figure 13: Italy Company Market Shares for Nuclear Imaging Equipment (2012) 205
Figure 14: Spain Company Market Shares for Nuclear Imaging Equipment (2012) 205
Figure 15: UK Company Market Shares for Nuclear Imaging Equipment (2012) 206
Figure 16: EU5 Market Value Forecast by Market Segment for SPECT & SPECT/CT (2012-2020) 207
Figure 17: EU5 Market Value Forecast by Market Segment for PET, PET/CT, and PET/MRI (2012-2020) 209
Figure 18: EU5 Sales of PET and SPECT Imaging Systems, 2012-2020 210
Figure 19: France Market Value Forecast by Market Subsegment (2012-2020) 212
Figure 20: Germany Market Value Forecast by Market Sub segment (2012-2020) 214
Figure 21: Italy Market Value Forecast by Market Sub segment (2012-2020) 217
Figure 22: Spain Market Value Forecast by Market Sub-segment (2012-2020) 220
Figure 23: UK Market Value Forecast by Market Sub-segment (2012-2020) 223
Figure 24: Primary Research Summary 264
Figure 25: Primary Research Participants Affiliation 265